Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Myelofibrosis
Recruiting3 awardsPhase 2
Boston, Massachusetts
This trial is testing Ruxolitinib as a possible treatment for Myelofibrosis, a disorder where the bone marrow doesn't make enough blood cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service